Cobra Biologics and KAHR Medical extend partnership

Published: 27-Jun-2012
Research & Development Pharmaceutical

To develop treatment for cancer and autoimmune diseases


Cobra Biologics, a manufacturer of biologics and pharmaceuticals, has announced a continuation of its partnership with KAHR Medical, based in Jerusalem, Israel.

KAHR is a developer of novel drugs based on Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases.

The extended collaboration will allow Cobra Biologics to advance KAHR-101 and KAHR-102 for future pre-clinical and clinical testing using Cobra Biologics’ maxXpress service.

Cobra Biologics will also be carrying out the process development and scale-up for the GMP production of KAHR-101 and KAHR-102.

  • Companies:
  • Cobra Biologics
  • KAHR Medical
See more

You may also like

Manufacturing

How will COVID-19 accelerate vaccine development? Part II

Read more
Jim Sanford, Dr Sade Mokuolu and Peter Birch from Watson-Marlow Fluid Technology Group (WMFTG) continue their investigation and pose the question: what will we learn from this pandemic and how will it change the course of vaccine production?

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  3. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  4. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  5. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

How will COVID-19 accelerate vaccine development? Part II

Jim Sanford, Dr Sade Mokuolu and Peter Birch from Watson-Marlow Fluid Technology Group (WMFTG) continue their investigation and pose the question: what will we learn from this pandemic and how will it change the course of vaccine production?
Manufacturing

CombiGene and Cobra sign agreement for GMP plasmid production

The agreement is part of preparations for GMP production of material for the first clinical study of CG01
Ingredients

Research partnership removes bottleneck from AAV development

CPI, Cobra Biologics and GE Healthcare Life Sciences have developed a scalable, cost-effective purification process for adeno-associated viruses
Manufacturing

Cobra Biologics and Symbiosis complete $6m collaboration

Partnership found synergies to improve the complexity, time and risk of drug substance and drug product viral vector production for gene and immunotherapy
Recruitment

CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies

Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Research & Development

A closer look at the Queen's Enterprise Award winners

The Queen’s Awards for Enterprise are considered by many to be the most prestigious business awards in the UK
Manufacturing

Cobra begins £15m gene therapy manufacturing expansion

Capacity increase in response to customer demand for DNA and viral vector production
Subscribe now